SOURCE: PreCision Dermatology

May 09, 2011 09:00 ET

PreCision Dermatology Strengthens Management Team With Key Hires for Onset Dermatologics

Industry Veterans Barry Calvarese and Jeff Wayne Bring More Than 60 Years of Leadership Experience to the Company

CUMBERLAND, RI--(Marketwire - May 9, 2011) - PreCision Dermatology, Inc., a leader in developing and commercializing novel, prescription and over-the-counter products for improving skin health, today announced several key appointments to its management team. Barry Calvarese has been named Executive Vice President, Research & Development and Chief Technology Officer, and Jeff Wayne has joined the Company as Senior Vice President and General Manager of Onset Dermatologics LLC, the prescription pharmaceutical subsidiary of PreCision.

"The addition of these two highly respected individuals significantly strengthens our ability to innovate and compete in the dynamic $6 Billion dermatology market," said Jeffrey Nugent, founding President and Chief Executive Officer of PreCision. "We are committed to providing real skincare solutions to physicians and their patients that deliver a high degree of patient satisfaction and ultimately improve adherence to therapy and clinical outcomes. I am confident that these additions will help us extend the reach of our products and propel the business into the next phase of growth."

Mr. Calvarese brings more than 30 years of dermatology, pharmaceutical, biotechnology and medical device industry experience to PreCision Dermatology. Prior to his current role, Mr. Calvarese served as Vice President of Clinical & Regulatory Affairs at Dow Pharmaceutical Sciences, Inc. (since acquired by Valeant Pharmaceuticals), where he oversaw clinical and preclinical development and managed the company's regulatory approval strategy and process. Mr. Calvarese was formerly Vice President of Regulatory, Clinical and Quality for Fibrinogen, Inc., where he was a member of the strategic and new product planning executive team and responsible for all clinical, regulatory and quality functions. He also previously held the position of Vice President of Regulatory Clinical Affairs and Quality Control/Assurance at Penederm, Inc., a dermatology-based start-up, where he focused on improving the company's long-term drug development and regulatory strategies. Mr. Calvarese has extensive experience through his work with other organizations including Collagen Corporation, Advanced Surgical Intervention, Inc., Advanced Biosearch Associates, Pfizer Hospital Products Group and the UCLA School of Medicine.

Prior to joining PreCision, Mr. Wayne was Senior Vice President of Sales and Marketing with Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories, Inc., where he was involved in every aspect of building the organization from the commercial infrastructure to product selection and development. Mr. Wayne is a 30-year veteran of the pharmaceutical industry and has spent the last 19 years of his career focused exclusively on dermatology. Beginning as a sales representative, Mr. Wayne progressed through the ranks of several specialty pharmaceutical and dermatology-focused companies including Sandoz, Lederle and Allergan, assuming positions of increasing responsibility in sales training, sales management, marketing and general management. Mr. Wayne previously held senior leadership positions at Galderma U.S., where he served as the Vice President of Marketing in the United States and at Galderma Canada, where he built and led the Canadian subsidiary.

"Barry and Jeff will bring a wealth of experience in clinical development, sales and marketing to our Company and we are confident that they will help us accelerate the development of highly effective skincare products that patients love to use," noted Mr. Nugent. "These accomplished industry executives will have a powerful impact on the success of both Precision Dermatology and Onset Dermatologics as we intensify our focus on developing innovative prescription dermatology products that advance healthy and beautiful skin."

Onset Dermatologics was recently acquired by PreCision Dermatology and has recently launched HylatopicPlus™ and the HylatopicPlus-Aurstat™ kit. The kit offers a convenient approach to treat patients with atopic dermatitis (eczema) and skin susceptible to S. aureus colonization.

About PreCision Dermatology, Inc.

Headquartered in Cumberland RI, PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology will expand quickly through acquisitions, in-licensing, co-marketing opportunities as well as internally generated therapies.

About Onset Dermatologics

Onset Dermatologics (www.onsetdermatologics.com) is dedicated to providing new, optimized, innovative, practical and cost-effective pharmaceutical products to the healthcare market in an effort to improve the quality of life for patients. The company markets 11 products based on its proprietary Delevo® foam technology platform that is designed to deliver enhanced penetration of proven active ingredients while improving patient compliance.

Contact Information